Avid Bioservices Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Adjusted EPS Results. Also, RBC Capital Maintained an Outperform Rating on the Stock and Raised Its Price Target From $8 to $12.
Avid Bioservices Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Adjusted EPS Results. Also, RBC Capital Maintained an Outperform Rating on the Stock and Raised Its Price Target From $8 to $12.
avid bioservices股票在公司報告超出預期的Q1調整後的每股收益結果後交易上漲。此外，RBC Capital維持股票的outperform評級，並將目標股價從$8上調至$12。
Avid Bioservices Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Adjusted EPS Results. Also, RBC Capital Maintained an Outperform Rating on the Stock and Raised Its Price Target From $8 to $12.
Avid Bioservices公佈的第一季度調整後每股收益好於預期後，該公司股價走高。此外，加拿大皇家銀行資本維持該股跑贏大盤的評級，並將其目標股價從8美元上調至12美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。